European Heart Journal Advance Access published online on April 27, 2006
European Heart Journal, doi:10.1093/eurheartj/ehi891
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Cardiology, Royal Free Hospital, Pond Street, London NW3 2QG, UK
* To whom correspondence should be addressed. Aims The aims of this study were to evaluate the diagnostic value and to explore the prognostic value of N-terminal brain natriuretic peptide (N-TproBNP) in patients with systemic sclerosis (SSc) both with and without pulmonary arterial hypertension (PAH). Methods and results N-TproBNP, six-minute walk distance (SMWD), haemodynamics (at right heart catheterization) or tricuspid gradient (by echocardiography), and survival were assessed in 109 patients with SSc. The study population included 68 individuals with PAH [mean pulmonary artery pressure (PAP) > 25 mmHg and pulmonary capillary wedge pressure <15 mmHg] and 41 individuals without PAH. In patients with PAH, the prognostic value of baseline and change in WHO functional class, N-TproBNP levels, and SMWD were compared using Kaplan-Meier survival curves and Cox proportional hazard analysis. The mean duration of follow-up was 10 months (range 1-18 months). One year survival in patients with normal PAP was 100% when compared with 83.5% in those with SSc-PAH (P<0.05). The patients without PAH had a mean N-TproBNP level of 139 pg/mL (SD 151); those with SSc-PAH had a significantly higher mean N-TproBNP level of 1474 pg/mL (SD 2642) (P=0.0002). Among patients with PAH for every order of magnitude increase in N-TproBNP level there was a four-fold increased risk of death (P=0.002 for baseline level and P=0.006 for follow-up level). Baseline N-TproBNP levels were correlated positively with mean PAP (r=0.62; P<0.0001), pulmonary vascular resistance (PVR) (r=0.81; P<0.0001), and inversely with SMWD (r=-0.46; P<0.0001). Among patients with SSc-PAH, 13 patients (19%) were in WHO functional classes II and had mean N-TproBNP levels of 325 pg/mL (SD 388). Fifty-three patients (78%) were in WHO classes III and IV and had significantly higher mean N-TproBNP levels of 1677 pg/mL (SD 2835) (P=0.02). At an N-TproBNP level of 395 pg/mL, the sensitivity and specificity for predicting the presence of SSc-PAH were 56 and 95% respectively. Conclusion Raised N-TproBNP levels are directly related to the severity of PAH. In screening programs, SSc patients with an N-TproBNP in excess of 395 pg/mL have a very high probability of having pulmonary hypertension. Baseline and serial changes in N-TproBNP levels are highly predictive of survival. A 10-fold increase in N-TproBNP level on therapy is associated with a greater than three-fold increase in mortality, and may indicate therapeutic failure.
Received November 18, 2005
Revised March 29, 2006
Accepted March 30, 2006
Clinical research
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension
Mark H. Williams 1,
Clive E. Handler 2,
Raza Akram 1,
Colette J. Smith 3,
Clare Das 2,
Joanna Smee 2,
Devaki Nair 4,
Christopher P. Denton 2,
Carol M. Black 2,
and
John G. Coghlan 1 *
2 Pulmonary Hypertension Service, Royal Free Hospital, Pond Street, London, UK
3 Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Rowland Hill Street, London, UK
4 Department of Clinical Biochemistry, Royal Free Hospital, Pond Street, London, UK
John G. Coghlan, E-mail: gerry.coghlan{at}royalfree.nhs.uk
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Authors/Task Force Members, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur. Heart J., October 2, 2009; 30(20): 2493 - 2537. [Full Text] [PDF]
|
|
|
|
 |
|
 J-L. Vachiery and G. Coghlan Screening for pulmonary arterial hypertension in systemic sclerosis Eur. Respir. Rev., September 1, 2009; 18(113): 162 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bijl, H. Bootsma, and C. G. M. Kallenberg Pulmonary arterial hypertension in systemic lupus erythematosus: should we bother? Rheumatology, August 26, 2009; (2009) kep258v1. [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Badesch, H. C. Champion, M. A. Gomez Sanchez, M. M. Hoeper, J. E. Loyd, A. Manes, M. McGoon, R. Naeije, H. Olschewski, R. J. Oudiz, et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S55 - S66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Matucci-Cerinic, V. Steen, P. Nash, and E. Hachulla The complexity of managing systemic sclerosis: screening and diagnosis Rheumatology, June 1, 2009; 48(suppl_3): iii8 - iii13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Warwick, P. S. Thomas, and D. H. Yates Biomarkers in pulmonary hypertension Eur. Respir. J., August 1, 2008; 32(2): 503 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Henkens, K. T. B. Mouchaers, A. Vonk-Noordegraaf, A. Boonstra, C. A. Swenne, A. C. Maan, S.-C. Man, J. W. R. Twisk, E. E. van der Wall, M. J. Schalij, et al. Improved ECG detection of presence and severity of right ventricular pressure load validated with cardiac magnetic resonance imaging Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2150 - H2157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Heart, March 1, 2008; 94(Suppl_1): i1 - i41. [Full Text] [PDF]
|
|
|
|
 |
|
 National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41. [Full Text] [PDF]
|
|
|
|
 |
|
 M T Carulli, C Handler, J G Coghlan, C M Black, and C P Denton Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis? Ann Rheum Dis, January 1, 2008; 67(1): 105 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.G. Coghlan and J. Davar How should we assess right ventricular function in 2008? Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H22 - H28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fijalkowska and A. Torbicki Role of cardiac biomarkers in assessment of RV function and prognosis in chronic pulmonary hypertension Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H41 - H47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Mathai and P. M. Hassoun N-terminal brain natriuretic peptide in scleroderma-associated pulmonary arterial hypertension Eur. Heart J., January 1, 2007; 28(1): 140 - 141. [Full Text] [PDF]
|
|
|
|
|
|
O. Distler and A. Pignone Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment Rheumatology, October 1, 2006; 45(suppl_4): iv22 - iv25. [Abstract] [Full Text] [PDF]
|
|